Jeremy Jones

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · The Lancet Oncology · 2019 · 502 citations · Full text

Medicine, Oncology, Pediatrics +16

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study

Jason Fangusaro, Arzu Onar‐Thomas, Tina Young Poussaint et al. · Neuro-Oncology · 2021 · 159 citations · Full text

Medicine, Oncology, Pediatrics +15

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease

Stephen J. Simko, Huy D. Tran, Jeremy Jones et al. · Pediatric Blood & Cancer · 2013 · 136 citations

Medicine, Hematology, Oncology +16

CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH‐associated neurodegeneration and mass lesions

Kenneth L. McClain, Jennifer Picarsic, Rikhia Chakraborty et al. · Cancer · 2018 · 134 citations · Full text

Medicine, Neurology, Pathology +17

Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy

Jillian R. Gunther, Mariko Sato, Murali Chintagumpala et al. · International Journal of Radiation Oncology*Biology*Physics · 2015 · 129 citations

Medicine, Oncology, Radiation Oncology +16